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Abstract
Background Published guidelines for the treatment of
healthcare-associated pneumonia (HCAP) recommend ini-
tial broad-spectrum antibiotics with appropriate de-esca-
lation based on culture results. Guideline recommendations
are based on data from intubated patients, in whom cultures
are easily obtained. The approach to antibiotic de-escala-
tion for culture-negative patients has not been addressed.
Consequently, there are no published reports that describe
the current standard of practice.
Patients and methods All patients admitted to a univer-
sity hospital with a diagnosis of HCAP, as deﬁned by use
of a pneumonia orderset, were identiﬁed retrospectively
over a 2-year period. Antibiotics prescribed on admission,
during hospital stay, and on discharge were recorded.
De-escalation was deﬁned as a change in the initial anti-
biotic therapy from broad- to narrow-spectrum coverage
within 14 days of the initial prescription. The Pneumonia
Severity Index was used for risk-adjustment.
Results A total of 102 patients were included in the
analysis; of these, 72% (n = 73) were culture-negative.
There were more males in the culture-negative than cul-
ture-positive group; otherwise, baseline characteristics
were similar. Antibiotic therapy was de-escalated in 75%
of the culture-negative group and 77% of the culture-
positive group (p = 1.00). Culture-negative patients were
de-escalated approximately 1 day earlier than culture-
positive patients (3.93 vs. 5.04 days, p = 0.03). Culture-
negative patients who were de-escalated had a shorter
length of hospitalization, lower hospital costs, and lower
mortality rates. In 70% of the culture-negative patients, a
respiratory ﬂuoroquinolone was chosen for de-escalation.
Conclusion In this single-center study, most of the
patients with culture-negative HCAP were safely de-esca-
lated to a respiratory ﬂuoroquinolone.
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Introduction
Healthcare-associated pneumonia (HCAP), as deﬁned by
guidelines published in 2005 by the American Thoracic
Society (ATS) and the Infectious Disease Society of
America (IDSA), describes a category of pneumonia in
which the risk for multidrug-resistant organisms is higher
thanforthosepatientswithcommunity-acquiredpneumonia
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DOI 10.1007/s15010-010-0042-z(CAP) [1]. Mortality rates for HCAP are twofold higher
than those with CAP [2–4]. The risk factors for HCAP
are detailed in Table 1.
A growing body of evidence demonstrates that the
choice of appropriate initial antibiotics has a signiﬁcant
impact on mortality rates for both CAP [5–7] and HCAP
[3, 4, 8]. A major focus of the guidelines [1] is to clarify the
empiric antibiotic regimens for clinicians that are most
likely to ensure adequate broad-spectrum coverage until
culture data are available to guide therapy. Unfortunately,
for most patients with pneumonia outside the intensive-
care unit, data based on cultures are inadequate or negative.
Based on data in published studies, blood cultures in
patients with pneumonia are positive \10% of the time
[9–11]. In addition, only about one-third of non-ventilated
patients are able to provide a sputum sample satisfactory
for analysis [12, 13], and of those, less than half yield a
predominant organism [12].
The guidelines clearly state that initial broad-spectrum
antibiotic regimens should be narrowed or ‘‘de-escalated’’
to cover the appropriate organisms identiﬁed by cultures
[1]. However, antibiotic de-escalation in culture-negative
patients is a topic the guidelines do not address. The
decision about how and when to de-escalate is left to
clinical judgment.
Given this limited beneﬁt of blood and sputum cultures
and the high incidence of multidrug-resistant organisms in
HCAP, some clinicians may be tempted to continue broad-
spectrum antibiotic regimens in patients who show clinical
improvement. This practice would need to be tempered by
concerns about selective pressure from prolonged exposure
to broad-spectrum antimicrobials leading to the develop-
ment of resistant microorganisms. Others, knowing that
patients with pneumonia rarely deteriorate once they have
achieved clinical stability [14], may elect to narrow cov-
erage early in stable culture-negative patients.
It is not clear which strategy is the most common or the
most appropriate. In the study reported here, we analyzed
practice patterns on antibiotic de-escalation for HCAP in
order to better understand the current clinical practice
landscape.
Patients and methods
A retrospective chart review was conducted at a university
medical center between July 2007 and February 2009. A
computerized physician order entry system was in place
during this period that contained an admission orderset
for patients with pneumonia. All patients C18 years old
admitted with HCAP, as identiﬁed by use of the orderset,
were enrolled in the study. The study was approved by the
university’s Institutional Review Board.
All data were collected through a review of electronic
and paper medical records. Demographics, length of stay,
inpatient mortality rates, results of sputum and blood cul-
tures, admission and discharge antibiotic prescriptions,
time to de-escalation of antibiotic therapy, and total cost of
stay were collected for each patient. For each case, the
speciﬁc risk factors for multidrug-resistant organisms or
HCAP, as detailed in Table 1, were recorded.
De-escalation of antibiotic therapy was deﬁned as a
change in antibiotic therapy from broad-spectrum HCAP
coverage [e.g., coverage of methicillin-resistant Staphylo-
coccus aureus (MRSA) and double-coverage of Pseudo-
monas] to a narrower spectrum regimen within 14 days of
the initial antibiotic prescription. Antibiotic prescription
data were reviewed by a licensed pharmacist, who judged
whether or not de-escalation had occurred.
Patients were divided into groups based on the results of
their blood and sputum cultures. Patients with growth of a
respiratory pathogen on any culture were considered to be
culture-positive;allotherswereconsideredasculture-negative.
In addition, a pneumonia severity index (PSI) score was
calculated for each patient to allow for risk-adjustment of
the data. The PSI is a validated tool used to predict 30-day
mortality for pneumonia patients [15]. PSI components are
assigned a numeric value and consist of age, sex, vital signs
(temperature, blood pressure, heart rate, respiratory rate,
altered mental status), past medical history (active cancer,
congestive heart failure, cerebrovascular disease, chronic
kidney/liver disease, residence at a skilled nursing facility),
laboratory parameters [glucose, blood urea nitrogen,
sodium, hematocrit, pH, pO2 or oxygen saturation], and the
presence of pleural effusion. All components are tallied and
assigned a PSI class ranging from I to V. PSI classes I–III
confer a low mortality risk, whereas, classes IV and V are
associated with 30-day mortality rates of 9 and 27%,
respectively.
Table 1 Risk factors for multidrug-drug resistant pathogens/HCAP
Bronchiectasis or other structural lung disease
Immunosuppressant disease or therapy
Antibiotic use within 90 days
Currently hospitalized[4 days
Hospitalized[1 day in past 3 months
Lives in skilled nursing facility/extended care
Receives home infusion therapy
Received chronic hemodialysis in the past 30 days
Receives home wound care
Family member with multi-drug resistant pathogen
Source: Adapted from American thoracic society and infectious dis-
eases society of America [1]
HCAP Healthcare-associated pneumonia
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± the standard deviation (SD) and analyzed with the t test
with 95% conﬁdence interval (CI) of the difference for
continuous normally distributed data. Medians and ranges
and the Wilcoxon rank-sum test were used for non-nor-
mally distributed continuous data. Proportions were ana-
lyzed with the Fischer’s exact test. A p value of\0.05 was
considered to be statistically signiﬁcant for all tests. The
Excel (Microsoft, Redmond, WA) spreadsheet and the
SPlus 6.2 (Insightful, Seattle, WA) statistical software
package were used for all data management and analysis.
Results
A total of 122 patients with an initial diagnosis of HCAP
were identiﬁed between July 2007 and February 2009. Of
these 122 patients, 102 were included in the analysis; the
remaining patients were excluded because HCAP was
ultimately ruled out as a diagnosis (Fig. 1).
Of the 102 patients, 72% (n = 73) fell in the culture-
negative group versus 28% (n = 29) in the culture-positive
group. There were signiﬁcantly more males in the culture-
negative group (p = 0.03); otherwise, baseline character-
istics and severity of illness were similar between the
groups (Table 2).
Culture-negative and culture-positive patients had sim-
ilar lengths of stay, 30-day readmission rates, and inpatient
mortality. The number of patients whose pneumonia was
fully treated prior to discharge were similar between
groups.
De-escalated patients
De-escalation to a narrow-spectrum antibiotic regimen
occurred in 75% (n = 55) of culture-negative patients and
77% (n = 22) of culture-positive patients (p = 1.00).
However, culture-negative patients were de-escalated
1 day sooner. Median time to de-escalation was 4 days in
the culture-negative group versus 5 days in the culture-
positive group, but this did not reach statistical signiﬁcance
(p = 0.17). The median number of HCAP risk factors was
higher in patients who were not de-escalated (2 vs. 1,
p = 0.003).
Moxiﬂoxacin was the most common antibiotic used
when antibiotic therapy was de-escalated. Overall, in the
combined groups, 62% of patients were de-escalated to
moxiﬂoxacin. In the culture-negative group, 70% of
patients transitioned to moxiﬂoxacin versus 41% in the
culture-positive group. There was no consistent pattern in
the use of other antibiotics for de-escalation (Fig. 2).
A combination of two or more antibiotics was used to
de-escalate 27% of patients in the culture-positive group
and 9% in the culture-negative group (Fig. 3).
Overall, patients whose antibiotic therapy was de-esca-
lated showed improved HCAP outcomes. For patients in
the de-escalated group, the hospital stay was shorter (7.1
vs. 13.0 days, p = 0.02) and total cost of care was lower
($31,644 vs. $62,524, p\0.001) than those in the non-
de-escalatedgroup.Atthesametime,therewasnodifference
in readmission rates within 30 days of hospital discharge
(p = 0.73) between the groups. Inpatient mortality was
signiﬁcantly lower in de-escalated patients (Table 3).
Culture-negative patients
Baseline characteristics and severity of illness in culture-
negative patients who were de-escalated were similar to
those who were not (Table 4). In the culture-negative
group, patients who were de-escalated had a shorter hos-
pital stay (5.8 vs. 14.2 days, p = 0.005) and lower total
cost of care ($28,286 vs. $80,791, p\0.001) than patients
who were not. At the same time, there was no difference in
30-day readmission rates (p = 1.00). Inpatient mortality
was signiﬁcantly lower in culture-negative de-escalated
patients (Table 4).
Discussion
In this observational study of antibiotic de-escalation for
patients with culture-negative HCAP, the majority of
patients had therapy narrowed to the hospital’s formulary
respiratory ﬂuoroquinolone, moxiﬂoxacin. Less than
10% of culture-negative patients were de-escalated to a
Fig. 1 Patients included in the analysis. HCAP Healthcare-acquired
pneumonia, COPD chronic obstructive pulmonary disease
Antibiotic de-escalation for HCAP 359multidrug regimen. Despite de-escalated patients having a
shorter stay in the hospital, there was no excess in 30-day
readmission rates, and inpatient mortality was lower by
almost a factor of 10 compared to the non-de-escalated
group (3 vs. 28%).
Approximately 20% of patients in our study continued
broad-spectrum therapy throughout their treatment course.
The design of our study did not allow us to determine the
reason why such patients were not de-escalated. The
severity of illness as measured by the PSI was not different
between groups; however, the number of HCAP risk fac-
tors was higher in the non-de-escalated group, suggesting
that factors other than the pneumonia likely impacted the
decision about therapy. It is reasonable to assume that at
least some patients had co-morbidities that required pro-
longed hospitalization or other medical diagnoses that
warranted continued use of broad-spectrum therapy despite
negative cultures.
However, it is notable that culture-positive patients were
not de-escalated any more frequently than culture-negative
patients, despite the clear direction in the guidelines to
narrow broad-spectrum therapy based on culture data [1].
Furthermore, despite positive cultures, clinicians took
1 day longer on average to narrow therapy in these
patients. Severity of illness was the same between groups.
Again, the retrospective nature of our study does not allow
us to clearly understand the reason for this delay. However,
the signiﬁcant cost differential (over $50,000 per case)
Table 2 Characteristics of culture-negative and culture-positive patients with HCAP
Patient characteristics Culture negative (n = 73) Culture positive (n = 29) p value Difference (95% CI)
Male sex, n (%) 41 (56) 9 (31) 0.03 25 (-7 to 52)
Age, years (mean ± SD) 58.4 ± 16.4 59.4 ± 16.9 0.80 -1.0 (-8.32 to 6.44)
HCAP RF (median) 2.0 2.0 0.54 0.0 (-0.01 to 0.01)
PSI score (mean ± SD) 87.6 ± 36.2 95.2 ± 39.4 0.37 -7.6 (-24.56 to 9.41)
LOS, days (mean ± SD) 7.9 ± 7.8 10.2 ± 13.2 0.39 -2.3 (-7.48 to 2.99)
Readmission within 30 days, n (%) 9 (12) 3 (10) 1.00 2 (-21 to 20)
Total cost, $ (median) 35,704 41,084 0.095 -5,380 (-22,654 to 2,422)
Inpatient mortality, n (%) 9 (12) 0 (0) 0.06 12 (-7 to 23)
CI Conﬁdence interval, SD standard deviation, RF risk factors; PSI pneumonia severity index; LOS length of stay
Fig. 2 Prescribing patterns for de-escalation therapy. a Combined
groups (culture-positive + culture-negative patients; n =7 7 ) .b Culture-
negative patients (n = 55)
Fig. 3 Antibiotic utilization for de-escalation therapy in patients with
HCAP. Gray-shaded column Culture-negative patients (n = 55),
open column culture-positive patients (n = 22), black-shaded column
combined groups (culture-positive ? culture-negative patients;
n = 77). Other Augmentin, azithromycin, cefepime, ceftazidime,
ciproﬂoxacin, levoﬂoxacin, linezolid, meropenem, vancomycin
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therapy, especially in light of the fact that mortality rates
were lower in de-escalated patients.
We have not identiﬁed any prospective studies comparing
treatment approaches for culture-negative HCAP in the cur-
rent literature. Expert consensus panels have convened to
review the evidence and found that there is currently insufﬁ-
cientdataonwhichtodeterminebestpractice[16].However,
therewasstrongconsensusamongpaneliststhatde-escalation
of culture-negative HCAP patients is appropriate when clin-
ical improvement is observed. Further outcomes-based stud-
ies in this area were recommended.
This study is limited by a small sample size and single-
center design and should be seen as a framework within
which to guide further research. Furthermore, the retro-
spective design made identiﬁcation of HCAP patients
challenging. There are currently no searchable ICD codes
for HCAP, which limits the utility of administrative data.
The use of the pneumonia orderset to identify patients
with HCAP risk factors was likely accurate, but physicians
admitting patients with pneumonia do not always use it to
enter the orders. Therefore, some patients would have been
missed with our study methodology. We did not do inde-
pendent chart conﬁrmation of the diagnosis of pneumonia;
use of the orderset by the admitting physician was the main
inclusion criteria. Although this may have led to the
inclusion of patients who did not actually have pneumonia,
this is unlikely, as the admission chest X-rays were
reviewed, and patients without abnormalities were exclu-
ded (see Table 1).
Also, we were only able to identify readmission to our
hospital; the 30-day readmission rates may be an under-
estimate if patients were re-hospitalized elsewhere. A
prospective study would allow for a more granular under-
standing of the issue of de-escalation, including data on the
reasons for antibiotic choices, for prolonged broad-spec-
trum therapy, and for prolonged length of stay.
Healthcare-associated pneumonia is relatively common
among hospitalized pneumonia patients, representing up to
25% of inpatient pneumonias in some studies [4]. At our
institution, the majority of stable culture-negative patients
with HCAP were safely de-escalated to a respiratory
ﬂuoroquinolone relatively early in the hospital course.
Whether this represents best practice is yet to be
Table 3 Characteristics of de-escalated patients with HCAP
Patient characteristics De-escalation (n = 77) No de-escalation (n = 25) p value Difference (95% CI)
Male sex, n (%) 39 (51) 11 (44) 0.65 7 (-26 to 38)
Age, years (mean ± SD) 59.0 ± 16.1 57.7 ± 17.7 0.75 1.3 (-9.39 to 6.78)
HCAP RF (median) 1.0 2.0 0.003 -1.0 (-1.01 to -0.01)
PSI score (mean ± SD) 87.3 ± 36.8 97.3 ± 37.7 0.25 -10 (-7.44 to 27.41)
LOS, days (mean ± SD) 7.1 ± 8.6 13.0 ± 11.0 0.02 -5.9 (-10.77 to -0.96)
Readmission within 30 days, n (%) 10 (13) 2 (8) 0.73 5 (-20 to 22)
Total cost, $ (median) 31,644 62,524 \0.001 -30,880 (-54,967 to -14,621)
Inpatient mortality, n (%) 2 (3) 7 (28) \0.001 -25 (-49 to -3)
CI conﬁdence interval; SD standard deviation; HCAP healthcare-associated pneumonia; RF risk factors; PSI pneumonia severity index;
LOS length of stay
Table 4 Characteristics of culture-negative patients with HCAP by antibiotic de-escalation status
Patient characteristics De-escalation (n = 55) No de-escalation (n = 18) p value Difference (95% CI)
Male sex, n (%) 33 (60) 8 (44) 0.28 16 (-23 to 51)
Age, years (mean ± SD) 59 ± 16 57 ± 18 0.65 2 (-11.75 to 7.49)
HCAP RF (median) 1.0 2.0 0.086 -1.0 (-0.01 to 0.99)
PSI score (mean ± SD) 84.4 ± 33.5 97.4 ± 42.8 0.25 -13.0 (-9.4 to 35.74)
LOS, days (mean ± SD) 5.8 ± 5.0 14.2 ± 10.9 0.005 -8.4 (-13.87 to -2.79)
Readmission rates within 30 days, n (%) 7 (13) 2 (11) 1.00 2 (-29 to 23)
Total cost, $ (median) 28,286 80,791 \0.001 -52,505 (-115,303 to -30,084)
Inpatient mortality, n (%) 2 (4) 7 (39) \0.001 -35 (-63 to -4)
CI conﬁdence interval; SD standard deviation; HCAP healthcare-associated pneumonia; RF risk factors; PSI pneumonia severity index;
LOS length of stay
Antibiotic de-escalation for HCAP 361determined. Larger, prospective, multicenter studies will
help clarify this question.
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